mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with Keytruda (pembrolizumab) was granted Priority Medicines scheme designation by the European Medicines Agency for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection.
In a recent multi-institutional clinical trial, 71% of patients who received the immunotherapy drug pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, before surgery had no detectable cancer remaining at the time of surgery.
